MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2--Advanced Breast Cancer.
Patrick NevenStephen R D JohnstonMasakazu ToiJoohyuk SohnKenichi InoueXavier PivotOlga BurdaevaMeena OkeraNorikazu MasudaPeter A KaufmanHan KohEva-Maria GrischkePierFranco ConteYi LuNadine HaddadKarla C HurtAntonio LlombartGeorge W SledgePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Consistent with the ITT population, a benefit in PFS and OS was observed across the first- and second-line subgroups in MONARCH 2.